Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Anatomic Stage IIIB Breast Cancer AJCC v8: early-phase trial registry
11 of 34 indexed Anatomic Stage IIIB Breast Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #451 of 28,707 conditions by registered trial count.
34 US clinical trials · 11 currently recruiting · #451 of 28,707 conditions by registered trial count
Anatomic Stage IIIB Breast Cancer AJCC v8: 34 US clinical trials tracked, 11 recruiting.
Anatomic Stage IIIB Breast Cancer AJCC v8 is the subject of 34 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 12 of these trials.
Enrollment posture brief
Registry condition anatomic-stage-iiib-breast-cancer-ajcc-v8
OPEN 11 | RECR 32% | LATE 2 | EARLY 15 | RANK #451 | SPON 12
Volume-matched condition peers
Nearest open-share peer: Hepatitis B (32% recruiting · 34 trials)
Anatomic Stage IIIB Breast Cancer AJCC v8 lists 11 open slots (32% of 34 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Anatomic Stage IIIB Breast Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Anatomic Stage IIIB Breast Cancer AJCC v8 is recruiting below its size-band peers.
11 of 34 indexed trials (32.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Anatomic Stage IIIB Breast Cancer AJCC v8 research.
M.D. Anderson Cancer Center accounts for 12 of 34 trials (35.3%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Anatomic Stage IIIB Breast Cancer AJCC v8 enrolment sits around 60 participants.
Median target enrolment is 60 among the 34 trials that report a genuine target (sentinel values excluded). 20 of those (58.8%) plan for fewer than 100 participants.
-
Anatomic Stage IIIB Breast Cancer AJCC v8 research is mostly interventional.
31 interventional and 3 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
34 total, page 1 of 1
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
SWOG Cancer Research Network
NCT05929768
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
University of Southern California
NCT07259304
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Mayo Clinic
NCT05269381
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
NCT04090567
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT05417308
A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment
University of Alabama at Birmingham
NCT05243056
Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors
University of Alabama at Birmingham
NCT05452681
Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
Emory University
NCT05368428
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Emory University
NCT06324240
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
NCT05319873
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
M.D. Anderson Cancer Center
NCT02918474
Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer
M.D. Anderson Cancer Center
NCT04678414
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
SWOG Cancer Research Network
NCT03939481
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT01334021
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Alliance for Clinical Trials in Oncology
NCT04457596
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
Alliance for Clinical Trials in Oncology
NCT04549571
Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors
Ohio State University Comprehensive Cancer Center
NCT04906200
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer
Thomas Jefferson University
NCT04086875
Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study
M.D. Anderson Cancer Center
NCT04754412
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
ECOG-ACRIN Cancer Research Group
NCT04001829
Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy
M.D. Anderson Cancer Center
NCT05049746
Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT03786354
Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
M.D. Anderson Cancer Center
NCT02971748
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
University of Washington
NCT05455658
Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
M.D. Anderson Cancer Center
NCT05025059
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03218826
Tibetan Yoga in Improving Fatigue and Sleep in Participants With Stage I-III Breast Cancer
M.D. Anderson Cancer Center
NCT00507923
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
Ohio State University Comprehensive Cancer Center
NCT04862585
An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors
Ohio State University Comprehensive Cancer Center
NCT05012176
Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer
Wake Forest University Health Sciences
NCT03505671
M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
M.D. Anderson Cancer Center
NCT03620201
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
NCT03207529
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
NCT03774472
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT04205903
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 6 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Anatomic Stage IIIB Breast Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Anatomic Stage IIIB Breast Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Anatomic Stage IIIB Breast Cancer AJCC v8 page
34 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Anatomic Stage IIIB Breast Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Anatomic Stage IIIB Breast Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anatomic Stage IIIB Breast Cancer AJCC v8 condition card totals 34 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.